Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $0.00 | $3.64M | $8.61M | $8.08M | $10.6M | $10.0M |
| Revenue growth | — | — | 136.8% | -6.1% | 31.0% | -5.6% |
| Operating income | -$4.84M | -$32.9M | -$67.1M | -$73.0M | -$98.8M | -$158M |
| Operating margin | — | -905.4% | -779.0% | -902.9% | -933.6% | -1576.7% |
| Net income | -$6.78M | -$32.7M | -$63.1M | -$58.3M | -$69.0M | -$114M |
| Net margin | — | -898.3% | -732.2% | -721.2% | -651.6% | -1136.3% |
| EPS (diluted) | -$7.41 | -$1.39 | -$1.52 | -$1.32 | -$1.28 | -$1.83 |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$4.37M | -$17.0M | -$42.9M | -$50.6M | -$43.8M | -$82.2M |
| Capital expenditures | $0.00 | $1.48M | $6.45M | $1.85M | $359K | $1.04M |
| Free cash flow | -$4.37M | -$18.5M | -$49.4M | -$52.4M | -$44.2M | -$83.3M |
| Fiscal year | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $7.81M | $35.6M | $51.4M | $19.2M | $431M | $52.3M |
| Total assets | $16.2M | $380M | $364M | $380M | $1.06B | $1.00B |
| Total liabilities | $9.23M | $13.5M | $43.3M | $36.1M | $38.7M | $44.7M |
| Shareholders' equity | -$14.6M | $366M | $321M | $344M | $1.02B | $957M |
| Retained earnings | -$14.7M | -$47.4M | -$110M | -$169M | -$238M | -$351M |
| Shares (wtd avg diluted) | 234K | 23.5M | 41.5M | 44.0M | 53.8M | 62.0M |
Every figure is extracted from Janux Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.